This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Gilead Sciences (GILD) and Savara (SVRA)

Tipranks - Tipranks - Tue Jun 16, 9:42AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on OrthoPediatrics (KIDS), Gilead Sciences (GILD) and Savara (SVRA) with bullish sentiments.

Claim 55% Off TipRanks

OrthoPediatrics (KIDS)

In a report issued on June 12, Mathew Blackman from TD Cowen maintained a Buy rating on OrthoPediatrics, with a price target of $23.00. The company’s shares closed last Monday at $17.72.

According to TipRanks.com, Blackman is a 4-star analyst with an average return of 8.2% and a 45.4% success rate. Blackman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Tandem Diabetes Care, and Beta Bionics, Inc. ;'>

Currently, the analyst consensus on OrthoPediatrics is a Strong Buy with an average price target of $24.63, a 38.1% upside from current levels. In a report issued on June 2, Canaccord Genuity also maintained a Buy rating on the stock with a $25.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Gilead Sciences (GILD)

In a report issued on June 12, Carter Gould from Cantor Fitzgerald maintained a Buy rating on Gilead Sciences, with a price target of $155.00. The company’s shares closed last Monday at $124.31.

According to TipRanks.com, Gould is a 4-star analyst with an average return of 5.3% and a 50.9% success rate. Gould covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Eli Lilly & Co. ;'>

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $160.37, implying a 28.0% upside from current levels. In a report issued on May 28, Wells Fargo also maintained a Buy rating on the stock with a $165.00 price target.

Savara (SVRA)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Savara today and set a price target of $10.00. The company’s shares closed last Monday at $5.41.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 20.8% and a 50.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Madrigal Pharmaceuticals. ;'>

Savara has an analyst consensus of Strong Buy, with a price target consensus of $11.17, implying a 108.0% upside from current levels. In a report issued on June 3, Oppenheimer also maintained a Buy rating on the stock with a $11.00 price target.

Read More on KIDS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).